Topical Insulin for Glaucoma

Trial ID or NCT#

NCT05206877

Status

recruiting iconRECRUITING

Purpose

The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).

Official Title

Topical Insulin for Glaucoma and Optic Neuropathies

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Capable to provide informed consent* Diagnosis of optic neuropathy either glaucoma or NAION or optic disc drusen.* Only one eye per patient will be selected as the study eye - if both eyes meet the inclusion criteria, the eye with the worse acuity and /or visual field will be selected. The contralateral eye will be left untouched.
Exclusion Criteria:
  1. * Pregnant or breastfeeding woman* Presence of any ocular pathologies other than glaucoma that contributes to the severe vision loss (retinopathy / maculopathy, severe uveitis, keratopathy, etc.)* Diagnosis of glucose intolerance, type 1 or 2 diabetes mellitus* Inability to perform reliable visual field* Unable to provide informed consent* Unable to complete the tests and follow-ups required by the study
View All Criteria
Show Less

Investigator(s)

Jeffrey Goldberg, MD, PhD
Jeffrey Goldberg, MD, PhD
Ophthalmologist
Blumenkranz Smead Professor

Contact us to find out if this trial is right for you.

Contact

Zac Wennberg-Smith

SEND MESSAGE

View on ClinicalTrials.gov